- AU$206.36m
- AU$169.56m
- AU$387.35m
Brief: Mayne Pharma Group Expects No Material Impact From Us S232 Tariffs
Australia's Mayne Pharma gains on flagging no material impact from latest US tariffs
Brief: Mayne Pharma Launches Distributerx In Us
Brief: Mayne Pharma Posts H1 Gross Margin 65.3%
Brief: Mayne Pharma Says Shawn Patrick O'Brien Stepped Down As CEO, Managing Director
Brief: Mayne Pharma To Claim Against Cosette, Others
Brief: Mayne Pharma Posts FY A$47M Underlying EBITDA
Brief: Australian Government Takeovers Panel Made Orders For Cosette
Brief: Mayne Pharma Receives Notice Of Appeal By Cosette Pharmaceuticals
Australia's Mayne Pharma hits over 2-year low on board resizing
Brief: Mayne Pharma Says Board Chair Frank Condella Has Decided To Retire
Brief: Mayne Pharma Says Net Revenues Were A$165 Million For First 5 Months Of FY26
Brief: Mayne Pharma Inaugurates Expanded Manufacturing Facility In Salisbury, South Australia
Brief: Mayne Pharma Terminates Scheme Implementation Deed With Cosette
Brief: Mayne Pharma Receives Purported Termination Notice From Cosette
Brief: Mayne Pharma Issues Notice Of Intention To Terminate Scheme Implementation Deed
Deals of the day-Mergers and acquisitions
After blocked Mayne deal, Australia M&As set for higher reverse break fees
Press Digest: Wall Street Journal - November 21